Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

NCT03990493 | Unknown Phase 1 DMC FDA Drug

• 1 other identifier: PV001-001 (Arm 3)
• Study Type: interventional
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this arm of the study is to evaluate the safety of PV-001-DC (autologous monocyte-derived dendritic cells pulsed with tumor lysate) when given in combination with PV-001-DV (Dengue Virus-1 strain #45AZ5) at the dose levels that were identified in the prior 2 arms and to determine if the combination can treat advanced melanoma. Patients will have a prescribed amount of PV-001-DV injected into one of their melanoma tumors. Patients will go to the clinic and have a needle placed in a vein. The PV-001-DC product will be infused into the patient's vein. Approximately every 3 weeks, for a total of 4 treatments, patients will receive additional infusions of PV-001-DC Patients will be at the clinic for at least 1 hour following the end of each PV-001-DC infusion and if they feel fine, they may go home. Approximately 49 days after the first infusion, patients will have a scan to see if their tumors have changed in size. Other scans may be performed during the study at different times. Patients will also have their blood and small samples of tumors tested for changes to the immune system. After 365 days, the trial will be completed for that patient.

Conditions

Advanced Melanoma

Outcome Measures

Primary Outcomes (1)

• Incidence and severity of Treatment-Emergent Adverse Events

  Treatment-Emergent Adverse Event Incidence of patients receiving intratumoral injection of PV-001-DV in combination with IV infusion of PV-001-DC

  365 days

Secondary Outcomes (3)

• Overall Response Rate (ORR)

  365 days

• Progression-Free Survival (PFS)

  365 days

• Overall Survival (OS)

  365 days

Study Arms (1)

PV-001-DV in Combination with PV-001-DC

EXPERIMENTAL

Intratumoral injection of PV-001-DV (1 injection) and IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)

Biological: Dengue Virus-1 #45AZ5 (PV-001-DV); Biological: Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)

Interventions

Dengue Virus-1 #45AZ5 (PV-001-DV) BIOLOGICAL

Intratumoral injection of PV-001-DV (1 injection)

PV-001-DV in Combination with PV-001-DC

Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC) BIOLOGICAL

IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)

PV-001-DV in Combination with PV-001-DC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Biopsy confirmed patients with un-resectable American Joint Committee on Cancer (AJCC), Stage III or IV melanoma who have measurable disease. Measurable disease is required, and is defined as tumor can be measured in one dimension along the longest diameter
• Patients must have tumors that are not responsive having completed prior therapy with a Progressive Death (PD)-1 / PD-Ligand-1 (PDL-1), antagonist alone or in combination with anti-Cytotoxic T Lymphocyte Antigen 4 (CTLA-4). If the patient is positive for BRAF, the patient must have progressed on at least one BRAF inhibitor in addition to a PD-1 / PD-L1 inhibitor alone or in combination with CTLA4 for metastatic melanoma
• Patients must be progressing after having completed one standard of care therapy for metastatic melanoma
• Tumor specimens must be available for tumor lysates and immunological studies.
• Tumors must be available for intratumoral injection of dengue virus. This includes cutaneous and subcutaneous lesions with ultrasound-guided injection.
• Eastern Cooperative Oncology Group (ECOG), Performance Status of ≤ 2 (corresponds to a Karnofsky Performance Status (KPS) of ≥ 70).
• Patients must be 18 years or older and able to give informed consent.
• Adequate bone marrow function of White Blood Cell (WBC) count to ≥ 1,500/microliter (uL); platelet count ≥ 100,000/mm3; absolute neutrophil count (ANC) \> 1,500/mm3
• Patients must have adequate renal function by serum creatinine of ≤ 2.0 milligrams/decaliter (mg/dL).
• Adequate hepatic function of bilirubin ≤ 2.5 mg/dL; Serum Glutamic Oxaloacetic acid Transaminase/ Serum Glutamic Pyruvic Transaminase (SGOT/SGPT) \< 3× upper limit of normal (ULN).
• Patients must have the required wash out periods from prior therapy:
• Topical therapy: 2 weeks.
• Chemotherapy and radiotherapy: 4 weeks.
• Other investigational therapy: 4 weeks
• Patients of reproductive potential and their partners must agree to use an effective (\>95% reliability) form of contraception during the study and for 4 weeks following the last study drug. Patients who become pregnant during the course of the study will be withdrawn from the trial.

You may not qualify if:

• Patients with positive antibody to any Dengue Virus serotype by tetravalent ELISA assay.
• Patients with prior vaccinations or positive Ab detected by ELISA to: West Nile, St. Louis Encephalitis, or Yellow Fever
• Pre-existing autoimmune or antibody mediated disease including systemic lupus erythematous, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.
• Known history of human immunodeficiency virus (HIV) or any active immunosuppressive systemic infection or a suppressed immune system, including acquired immuno-deficiency syndrome (AIDS) or HIV positivity and known hepatitis B or C infections (HCV or HBC), as assessed by serology.
• Patients on immunosuppressive therapy. Concurrent steroid use of not more than an equivalent of 10 mg of prednisone is allowed.
• Any other open wounds.
• Previous organ transplantation.
• Patients with clinically significant dermatological disorders, as judged by the clinical investigator (e.g., eczema or psoriasis), any skin lesions or ulcers, any history of atopic dermatitis, or any history of Darier's disease (Keratosis Follicularis).
• Patients with White Blood Cell count \<1,500/uL; platelet count \<100,000/mm3; absolute neutrophil count (ANC) 1,500/mm3 (Grade 2)
• Patients with inadequate renal function by serum creatinine of \>1.5 x ULN (Grade 2)
• Patients with inadequate liver function by SGPT/SGOT \> 3x ULN, and bilirubin \>2.5 mg/dl (Grade 2)
• Patients with active infection or with a fever \>101°F (38.5°C) within 3 days prior to the first scheduled treatment.
• Concurrent participation in other treatment related clinical studies. Non-treatment studies (e.g. observation or tumor cell analysis studies) are allowed.
• Prior malignancy (active within 3 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix.
• Significant cardiovascular disease (i.e., New York Heart Association (NYHA) class 3 congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).

Sponsors & Collaborators

• PrimeVax Immuno-Oncology Inc.: lead
• Walter Reed Army Institute of Research (WRAIR): collaborator

Central Study Contacts

Bruce W Lyday

CONTACT

(714) 585-7485; bruce.lyday@primevax.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Single Group Assignment with Dose Modification

Study Record Dates

• First Submitted: June 12, 2019
• First Posted: June 19, 2019
• Study Start: April 1, 2024
• Primary Completion: September 30, 2024
• Study Completion: December 31, 2024
• Last Updated: July 6, 2023

Record last verified: 2023-07